Aflac Incorporated

The annual figures and the 2026 interim filings point in different directions, so a careful reader should keep both in view. For fiscal 2025, revenues were $17.16 billion, down 9.3% from $18.93 billion, and net income was $3.65 billion, down from $5.44 billion. The forensic scores need to be read one at a time. The Beneish M-Score is -2.552, below the -1.78 threshold and therefore not in the elevated manipulation-risk zone. That is a screening result, not proof that the numbers are accurate. The Altman Z-Score is 1.31, in the distress zone, but Altman Z is not designed for insurers, so it should be treated with caution rather than read as a going-concern signal. The Piotroski F-Score is 3 of 6 computable signals, a partial reading that says little on its own. The Fog Index of 18.42 falls in the very hard to read band, which matters because the MD&A is where management explains the yen and investment-loss swings. Aflac's principal business is supplemental health and life insurance through Aflac Japan and Aflac U.S., with Aflac Re Bermuda reinsuring policies issued by Aflac Life Insurance Japan. Readers may want to look at the risk factor on concentration of business in Japan, the yen/dollar sensitivity, the June 2025 U.S. Cyber Incident, and the litigation risk tied to worker misclassification allegations. Equity rose to $29.49 billion at December 31, 2025, from $26.1 billion a year earlier, but the MD&A attributes $8.0 billion of that base to cumulative discount rate effects, so the reported rise is not a clean read of underlying book value.

Catalyst.The MD&A shows a sharp swing in first-half 2026 earnings, driven mainly by investment results. Net earnings were $1.8 billion ($3.61 per diluted share) for the six months ended June 30, 2026, versus $628 million a year earlier. Net investment losses narrowed to $104 million from $1.4 billion. Adjusted earnings were $1.8 billion ($3.50 per diluted share) versus $1.9 billion ($3.43 per share). Second-quarter total revenues were $4.1 billion, compared with $4.2 billion in the second quarter of 2025. A weaker yen, with an average rate of 158.14 per dollar in the first half (6.2% weaker than a year earlier), reduced adjusted earnings per diluted share by $.07. The company also repurchased $2.0 billion of its shares in the first six months of 2026.

Hidden risk.The 2025 annual figures show revenues down 9.3% to $17.16 billion and net income down to $3.65 billion from $5.44 billion. Operating cash flow was $2.56 billion, so operating cash flow divided by net income was 0.70, meaning cash from operations ran below reported profit. The MD&A's adjusted book value excluding foreign currency remeasurement fell to $20.7 billion at June 30, 2026, from $22.1 billion at December 31, 2025, even as reported equity rose. Much of reported equity depends on discount rate assumption changes on insurance reserves, which the MD&A puts at a cumulative $10.4 billion at June 30, 2026. The June 2025 U.S. cyber incident also has an ongoing financial impact assessment.